A modern biomarker may help identify which pancreatic cancer patients respond to CD40 agonists
Inflammation in the blood could be a new biomarker to help identify patients with advanced pancreatic cancer who do not respond to the immune stimulating drugs called CD40 agonists, suggests a new …
